表纸
市场调查报告书
商品编码
362372

急性骨髓灰白质炎 (小儿麻庳) :开发中产品分析

Poliomyelitis (Infectious Disease) - Drugs in Development, 2021

出版日期: | 出版商: Global Markets Direct | 英文 104 Pages | 订单完成后即时交付

价格

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

  • 全貌
  • 简介
  • 目录
简介

本报告提供急性骨髓灰白质炎 (小儿麻庳) 治疗药的开发情形相关调查,提供您开发中产品概要,各临床实验阶段的产品概要,主要企业及药物简介,开发中产品的最新趋势,及最新消息/新闻稿等资讯。

简介

  • 调查范围

急性骨髓灰白质炎 (小儿麻庳)的概要

治疗药的开发

  • 开发中产品的概要
  • 开发中产品比较分析

急性骨髓灰白质炎 (小儿麻庳) :企业开发中的治疗药

急性骨髓灰白质炎 (小儿麻庳) :大学/机关研究中的治疗药

急性骨髓灰白质炎 (小儿麻庳) :开发中产品概况

  • 后期阶段的产品
  • 临床阶段的产品
  • 初期阶段的产品

急性骨髓灰白质炎 (小儿麻庳) :企业开发中的产品

急性骨髓灰白质炎 (小儿麻庳) :大学/机关研究中的产品

急性骨髓灰白质炎 (小儿麻庳)的治疗药的开发企业

  • Beijing Minhai Biotechnology Co., Ltd
  • Beijing Tiantan Biological Products Co., Ltd.
  • Bharat Biotech International Limited
  • Bilthoven Biologicals B.V.
  • Biological E. Limited
  • Boryung Pharmaceutical Co., Ltd.
  • Codagenix, Inc.
  • 第一三共
  • Grifols, S.A.
  • Johnson & Johnson
  • LG Life Science LTD.
  • Nanolek, LLC
  • Panacea Biotec Limited
  • Sanofi Pasteur SA
  • Sentinext Therapeutics Sdn Bhd
  • Sinovac Biotech Ltd.
  • Taiga Biotechnologies, Inc.

急性骨髓灰白质炎 (小儿麻庳) :治疗药的评估

  • 单剂产品
  • 组合产品
  • 标的别
  • 各给药途径
  • 各分子类型

药物简介

急性骨髓灰白质炎 (小儿麻庳) :最近的开发平台趋势

急性骨髓灰白质炎 (小儿麻庳) :暂停中的计划

急性骨髓灰白质炎 (小儿麻庳) :开发中止的产品

急性骨髓灰白质炎 (小儿麻庳) :产品开发的里程碑

  • 主要消息和新闻稿

附录

目录
Product Code: GMDHC13194IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Poliomyelitis - Drugs In Development, 2021, provides an overview of the Poliomyelitis (Infectious Disease) pipeline landscape.

Polio is a highly infectious disease caused by a virus. It invades the nervous system and causes total paralysis in a matter of hours. Symptoms include fever, fatigue, headache, vomiting, stiffness in the neck and pain in the limbs. Preventive measures such as the use of vaccines are effective for polio.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Poliomyelitis - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Poliomyelitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Poliomyelitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Poliomyelitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 7, 7, 3, 5 and 4 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 3, 4, 2, 3 and 1 molecules, respectively.

Poliomyelitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Poliomyelitis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Poliomyelitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Poliomyelitis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Poliomyelitis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Poliomyelitis (Infectious Disease)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Poliomyelitis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Poliomyelitis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Poliomyelitis - Overview
  • Poliomyelitis - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Poliomyelitis - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Poliomyelitis - Companies Involved in Therapeutics Development
  • Poliomyelitis - Drug Profiles
  • Poliomyelitis - Dormant Projects
  • Poliomyelitis - Discontinued Products
  • Poliomyelitis - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

List of Tables

  • Number of Products under Development for Poliomyelitis, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Companies, 2021 (Contd..1)
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Poliomyelitis - Pipeline by Beijing Minhai Biotechnology Co Ltd, 2021
  • Poliomyelitis - Pipeline by Beijing Tiantan Biological Products Co Ltd, 2021
  • Poliomyelitis - Pipeline by Bharat Biotech Ltd, 2021
  • Poliomyelitis - Pipeline by Biken Co Ltd, 2021
  • Poliomyelitis - Pipeline by Biological E Ltd, 2021
  • Poliomyelitis - Pipeline by Biological Mimetics Inc, 2021
  • Poliomyelitis - Pipeline by Boryung Pharmaceutical Co Ltd, 2021
  • Poliomyelitis - Pipeline by CanSino Biologics Inc, 2021
  • Poliomyelitis - Pipeline by GlaxoSmithKline Plc, 2021
  • Poliomyelitis - Pipeline by Grifols SA, 2021
  • Poliomyelitis - Pipeline by Helix Biogen Institute, 2021
  • Poliomyelitis - Pipeline by Johnson & Johnson, 2021
  • Poliomyelitis - Pipeline by KM Biologics Co Ltd, 2021
  • Poliomyelitis - Pipeline by LG Chem Ltd, 2021
  • Poliomyelitis - Pipeline by Micron Biomedical Inc, 2021
  • Poliomyelitis - Pipeline by Nanolek LLC, 2021
  • Poliomyelitis - Pipeline by Panacea Biotec Ltd, 2021
  • Poliomyelitis - Pipeline by Serum Institute of India Pvt Ltd, 2021
  • Poliomyelitis - Pipeline by Shantha Biotechnics Pvt Ltd, 2021
  • Poliomyelitis - Pipeline by Statera BioPharma Inc, 2021
  • Poliomyelitis - Pipeline by Univercells SA, 2021
  • Poliomyelitis - Pipeline by Vaxxas Inc, 2021
  • Poliomyelitis - Pipeline by Wuhan Institute of Biological Products Co Ltd, 2021
  • Poliomyelitis - Dormant Projects, 2021
  • Poliomyelitis - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Poliomyelitis, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Targets, 2021
  • Number of Products by Stage and Targets, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021